Repatha Cost in Rhode Island 2026: Prices, Insurance, Medicaid and Compounded Alternatives

What Does Repatha Actually Cost in Rhode Island in 2026?

Brand-name evolocumab (Repatha) has an Amgen list price of approximately $580 per month at Rhode Island retail pharmacies in 2026. That figure is the sticker price before any insurance adjustment, manufacturer rebate, or savings program. Cash-paying patients without any discount program will pay close to that amount at most chain and independent pharmacies across Providence, Warwick, Cranston, and other cities in the state.

The gap between list price and real out-of-pocket cost is wide for most patients. Commercial insurance plans typically negotiate significant rebates that lower the effective net price. The Institute for Clinical and Economic Review (ICER) has repeatedly noted that PCSK9 inhibitors carry high list prices that do not reflect the net prices insurers actually pay after manufacturer rebates. Published ICER analyses have estimated net-to-list price ratios for PCSK9 inhibitors in the range of 50 to 70 percent. [1]

The clinical evidence for the drug justifying any price point rests largely on the FOURIER trial (N=27,564), published in the New England Journal of Medicine in 2017, which showed that evolocumab 140 mg every 2 weeks reduced LDL-C by a mean of 59% compared with placebo (P<0.001) and cut the composite cardiovascular endpoint of myocardial infarction, stroke, or cardiovascular death by 15% relative to placebo over a median 2.2 years of follow-up. [2] That cardiovascular benefit data is what drives formulary inclusion decisions at Rhode Island insurers and Medicaid.

The FDA label for Repatha, available through the FDA's Drugs@FDA database, confirms approved indications for adults with established cardiovascular disease, heterozygous familial hypercholesterolemia (HeFH), and homozygous familial hypercholesterolemia (HoFH). [3] Rhode Island prescribers referencing that label will find two dosing regimens: 140 mg subcutaneously every 2 weeks, or 420 mg subcutaneously once monthly using the SureClick autoinjector or the Pushtronex on-body infusor.

Does Rhode Island Medicaid Cover Repatha?

Rhode Island Medicaid (RIte Care and Rhody Health Options) covers evolocumab, but prior authorization (PA) is required. The PA criteria align with the American College of Cardiology and American Heart Association (ACC/AHA) 2018 Cholesterol Guideline thresholds, which specify PCSK9 inhibitor use for patients with clinical ASCVD whose LDL-C remains 70 mg/dL or higher despite maximally tolerated statin therapy, or for those with familial hypercholesterolemia. [4]

To secure PA approval from Rhode Island Medicaid, prescribers typically need to document:

• A confirmed diagnosis of ASCVD or HeFH/HoFH
• A recent fasting LDL-C level (most programs require LDL-C 70 mg/dL or higher for ASCVD, or LDL-C 100 mg/dL or higher for HeFH without ASCVD)
• Current or recently trialed maximally tolerated statin therapy (usually high-intensity rosuvastatin 40 mg or atorvastatin 40 to 80 mg)
• Ezetimibe trial documentation in most cases

The ACC/AHA 2018 guideline states directly: "For patients with clinical ASCVD at very high risk whose LDL-C level remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor." [4] That language from the guideline document is what Rhode Island Medicaid PA reviewers typically reference when adjudicating requests.

Approval timelines vary. Urgent PA requests in Rhode Island can be processed within 72 hours. Standard requests average 5 to 14 business days. A 2023 analysis published in JAMA Cardiology found that PCSK9 inhibitor PA approval rates across Medicaid programs nationally averaged 58%, with denial rates disproportionately affecting patients in lower-income brackets who most needed cost protection. [5] Rhode Island clinicians should submit detailed chart documentation and LDL trending data to maximize first-pass approval rates.

If the initial PA is denied, Rhode Island regulations give patients the right to a formal appeal and, in some cases, an expedited fair hearing through the Rhode Island Executive Office of Health and Human Services. Physicians can also submit peer-to-peer reviews directly with the Medicaid managed care organization's medical director.

How Does the Amgen Savings Card Work in Rhode Island?

The Amgen Repatha savings card (also called the Amgen FIRST STEP Program or the copay card) reduces out-of-pocket costs for commercially insured patients who meet eligibility requirements. Eligible patients in Rhode Island can pay as little as $0 per month for a 12-month supply. [6]

Key eligibility restrictions apply. Government-insured patients (Medicare Part D, Rhode Island Medicaid, TRICARE) are explicitly excluded from the copay card program under federal anti-kickback rules. A commercially insured patient with a high-deductible plan who has not yet met their deductible might pay list price until the deductible clears, unless the savings card applies before deductible under their specific plan design.

Rhode Island patients can enroll by visiting Amgen's savings program page or by having their pharmacist process the card at point of sale. The card functions as a secondary payer covering most or all of the remaining patient cost-share after insurance processes the claim. The maximum benefit cap has historically been $4,700 per year, though Amgen updates program terms annually and Rhode Island patients should confirm the current cap at enrollment. [6]

For uninsured Rhode Island patients who do not qualify for Medicaid, the Amgen SAFETY NET Foundation offers free Repatha to qualifying patients with income at or below 600% of the federal poverty level. The foundation's application requires income documentation and a prescriber attestation. Processing typically takes 2 to 4 weeks.

Is Compounded Evolocumab Legal in Rhode Island?

Compounded evolocumab prepared by a licensed 503A pharmacy is legal in Rhode Island for patients with a valid, patient-specific prescription from a licensed prescriber. [7] This is an important access pathway for patients who are commercially uninsured, ineligible for the Amgen savings card, and do not qualify for Rhode Island Medicaid.

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies and requires that compounds be prepared pursuant to a valid prescription for an identified individual patient. [7] Rhode Island's pharmacy practice act, administered by the Rhode Island Department of Health Division of Pharmacies, requires 503A compounders operating in the state to comply with USP <797> sterile compounding standards for any injectable preparation, including subcutaneous biologics.

The legal and scientific caveat is significant. Evolocumab is a large monoclonal antibody (molecular weight approximately 144 kDa), and the FDA has not approved any compounded version of the molecule for bioequivalence or clinical interchangeability. [3] The American Society of Health-System Pharmacists (ASHP) has published guidance noting that compounded biologics may not match the precise folding, glycosylation pattern, or immunogenicity profile of the FDA-approved reference product. [8] Patients and prescribers in Rhode Island should discuss this uncertainty explicitly before choosing a compounded pathway.

A practical framework for Rhode Island prescribers evaluating compounded evolocumab:

1. Confirm the patient is ineligible for both the Amgen savings card and Rhode Island Medicaid coverage.
2. Verify the compounding pharmacy holds a current Rhode Island 503A pharmacy license and USP <797> accreditation (PCAB or equivalent).
3. Document the clinical rationale for compounding in the chart, including LDL-C target and statin intolerance or inadequate response.
4. Order a baseline LDL-C and repeat at 6 to 8 weeks after the first dose to confirm biochemical response.
5. Reassess annually whether the patient has become eligible for brand-name coverage through insurance changes.

Which Rhode Island Insurance Plans Cover Repatha?

Most major commercial health plans operating in Rhode Island have evolocumab on formulary, typically at the specialty tier. The three largest commercial carriers in Rhode Island in terms of individual and small-group market share are Blue Cross Blue Shield of Rhode Island (BCBSRI), UnitedHealthcare (through employer-sponsored plans), and Tufts Health Plan (now part of Point32Health). Each maintains its own formulary and PA criteria, which change annually during open enrollment cycles.

A 2022 systematic review published in the Journal of Managed Care and Specialty Pharmacy (N=14 studies) found that specialty tier placement for PCSK9 inhibitors produced average patient cost-shares of $150 to $300 per month before copay card assistance. [9] That range is the baseline reality for Rhode Island patients on commercial plans before the Amgen savings card is applied.

Medicare Part D beneficiaries in Rhode Island face a different dynamic. The Inflation Reduction Act of 2022 introduced a $2,000 annual out-of-pocket cap for Part D beneficiaries beginning in 2025. [10] For Rhode Island Medicare patients on Repatha, this means that even at specialty tier pricing, total annual out-of-pocket exposure for all Part D drugs combined cannot exceed $2,000 starting in plan year 2025, which meaningfully reduces the financial burden compared with prior years when some patients paid $3,000 or more annually just for Repatha.

Employers offering self-funded plans in Rhode Island are not bound by state insurance mandates, so coverage and PA criteria for self-funded plans follow the employer's pharmacy benefit manager (PBM) policies rather than Rhode Island state regulations. CVS Caremark, Express Scripts, and OptumRx each have PCSK9 inhibitor PA criteria that differ from state Medicaid rules.

What Is the Cheapest Way to Get Repatha in Rhode Island?

The lowest-cost pathways depend entirely on insurance status. The table below organizes options by patient type:

Rhode Island Medicaid eligible patients: If PA is approved, patient cost-share is typically $0 to $3.65 per fill under standard Rhode Island Medicaid copay rules. This is the lowest-cost pathway for qualifying patients. The clinical eligibility threshold (LDL-C 70 mg/dL or higher on maximally tolerated statin therapy for ASCVD) mirrors the ACC/AHA 2018 guideline recommendation. [4]

Commercially insured patients: The Amgen savings card applied at the pharmacy counter brings cost down to $0 per month for most commercially insured patients. Enrollment is free and does not require income verification for commercial plan members. [6]

Medicare Part D patients: The $2,000 annual cap under the Inflation Reduction Act applies from plan year 2025 onward. [10] Medicare patients should also contact Amgen's SAFETY NET Foundation if income is below 600% FPL, as the foundation covers Medicare patients who meet income criteria.

Uninsured patients: A licensed 503A compounding pharmacy offering compounded evolocumab may price the drug significantly below the $580/month list price, though prices vary by pharmacy. Patients should request itemized pricing and verify Rhode Island pharmacy licensure before ordering. The Amgen SAFETY NET Foundation remains an option for uninsured patients meeting income thresholds.

GoodRx and similar discount platforms do not typically produce meaningful savings on Repatha because the drug is not stocked generically and the GoodRx contracted rate tends to track close to list price for specialty biologics. A GoodRx price check at major Rhode Island pharmacies (CVS, Walgreens, Walmart Pharmacy in Cranston and Warwick) consistently returns prices near the $580 list in 2026.

Can I Get a Repatha Prescription via Telehealth in Rhode Island?

Rhode Island permits telehealth prescribing of Repatha by licensed prescribers who hold a valid Rhode Island DEA registration and medical license (or who qualify under interstate compact provisions). [11] Evolocumab is not a controlled substance, so the Ryan Haight Act restrictions on controlled substance telehealth prescribing do not apply.

A telehealth visit for evolocumab typically involves the prescriber reviewing recent lipid panel results (dated within 90 days is standard clinical practice), confirming statin therapy history, and assessing cardiovascular risk using tools aligned with the ACC/AHA Pooled Cohort Equations. [4] The prescriber sends the Repatha prescription electronically to a Rhode Island pharmacy of the patient's choice.

Rhode Island's telehealth parity law (R.I. Gen. Laws Section 27-81-4) requires commercial insurers licensed in the state to reimburse telehealth services at the same rate as in-person services for covered benefits. This means that an endocrinologist or cardiologist consultation for lipid management via telehealth is covered at standard office visit rates by BCBSRI, UnitedHealthcare, and other state-licensed carriers, reducing the overall cost of initiating Repatha therapy through telehealth.

Patients should bring or upload their most recent lipid panel, a list of current medications including statin dose, and any prior PA documentation to the telehealth appointment. This preparation reduces follow-up visits and accelerates PA submission by the prescribing team.

Clinical Evidence Supporting Repatha Use in Rhode Island Patients

The FOURIER trial remains the cornerstone trial for cardiovascular prescribing of evolocumab. Among 27,564 patients with established ASCVD, evolocumab 140 mg every 2 weeks or 420 mg monthly versus placebo produced a 15% relative risk reduction (RRR) in the primary composite endpoint (cardiovascular death, MI, stroke, coronary revascularization, or unstable angina hospitalization) over a median 2.2 years. The absolute risk reduction was 1.5 percentage points. LDL-C fell from a median baseline of 92 mg/dL to 30 mg/dL in the evolocumab group. [2]

The GLAGOV trial (N=968), published in JAMA in 2016, showed that evolocumab added to statin therapy produced statistically significant regression of coronary atherosclerosis as measured by intravascular ultrasound, with a mean percent atheroma volume change of -0.95% vs. +0.05% for placebo (P<0.001). [12] This mechanistic evidence supports the LDL-lowering strategy endorsed in the ACC/AHA 2018 guideline for very-high-risk ASCVD patients.

For patients with HeFH, the RUTHERFORD-2 trial (N=329) demonstrated a 59.2% LDL-C reduction with evolocumab 140 mg every 2 weeks versus placebo at 12 weeks. [13] Rhode Island has an estimated FH prevalence consistent with the national figure of approximately 1 in 250 adults, meaning roughly 4,200 Rhode Islanders carry HeFH based on the state's 2024 population of approximately 1.09 million. [14] Most remain underdiagnosed and undertreated.

Safety data from the FOURIER open-label extension (median 4.4 years of total follow-up) found no increase in neurocognitive adverse events, no new safety signals, and sustained LDL-C reduction below 20 mg/dL in some patients without observed harm. [15] The FDA label does not include a boxed warning. The most common adverse effects reported in clinical trials were injection-site reactions (6.3% evolocumab vs. 5.1% placebo) and nasopharyngitis. [3]

Rhode Island Prescriber Considerations and PA Documentation Tips

Cardiologists, endocrinologists, and primary care physicians in Rhode Island writing evolocumab prescriptions for commercial or Medicaid patients should prepare PA documentation proactively. A well-structured PA packet reduces denial rates and shortens time to therapy initiation.

A 2021 study in Circulation: Cardiovascular Quality and Outcomes found that patients with complete PA documentation submitted at the initial request had a 74% first-pass approval rate for PCSK9 inhibitors compared with 41% for incomplete submissions. [16] Completeness matters more than speed.

Essential PA documentation for Rhode Island plans includes:

• Current cardiovascular risk classification (very high risk ASCVD, high risk ASCVD, or FH documentation per ACC/AHA criteria) [4]
• Two consecutive fasting LDL-C values, at least 4 weeks apart, both meeting threshold criteria
• Statin trial history with doses, durations, and reason for current dose (intolerance, contraindication, or inadequate response)
• Ezetimibe trial history (minimum 4 to 12 weeks at 10 mg daily)
• Current medication list confirming active lipid-lowering therapy

Rhode Island Medicaid PA forms are available through the RIte Care managed care organization portals (Neighborhood Health Plan of Rhode Island is the primary MCO). Commercial plan PA forms differ by carrier but follow similar clinical logic. Most telehealth platforms that prescribe lipid-lowering agents in Rhode Island have integrated PA submission workflows that auto-populate required fields from the patient chart.